Docetaxel
Microtubule stabilizing agent / Antimitotic chemotherapeutic which inhibits via reversible high-affinity binding to microtubules1. Induces apoptosis in a variety of cancer cell lines2 however, tumor cells can quickly develop resistance to docetaxel via several mechanisms3,4. Can act in synergy with a variety of other anticancer agents including kinase inhibitors.5,6
Biochemicals & reagents
114977-28-5
Taxotere; RP-56976; NSC-628503
1) Fabbri et al. (2008), Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells; J. Cell Physiol, 217 494. / 2) Dosso and Berthold (2008), Docetaxel in the management of prostate cancer: current standard of care and future directions ; Expert Opin. Pharmacother, 9 1969 / 3) Homma et al. (2008), RPN2 gene confers docetaxel resistance in breast cancer; Nat. Med., 14 939 / 4) Kars et al. (2008), Reversal of Multidrug Resistance by Synthetic and Natural Compounds in Drug-Resistant MCF-7 Cell Lines Chemotherapy, 54 194 / 5) Wallin et al. (2012), GDC-0941, A Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In vitro and In Vivo; Clin Cancer Res., May 14: Epub ahead of print. / 6) Heinemann et al. (2011), Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer; BMC Cancer, 11 221
-20°C
TARGET: Cytoskeleton -- PATHWAY: Apoptosis inducer -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer